Filip Krag Knop

Filip Krag Knop

Clinical Professor

Member of:

  • Internal Medicine: Endocrinology


Publication year:
All
1 - 10 out of 17Page size: 10
Sort by: 1st author
  1. Published

    Bile-induced secretion of glucagon-like peptide-1: pathophysiological implications in type 2 diabetes?

    Knop, Filip Krag, 1 Jul 2010, In: American Journal of Physiology: Endocrinology and Metabolism. 299, 1, p. E10-3

    Research output: Contribution to journal › Journal article › Research › peer-review

  2. Published

    Comment on: Villareal et al. (2009) TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action. Diabetes;59:479-485

    Knop, Filip Krag, 1 Jun 2010, In: Diabetes. 59, 6, p. e4; author reply e5-6

    Research output: Contribution to journal › Letter › Research › peer-review

  3. Published

    Incretin hormones and beta cell function in chronic pancreatitis

    Knop, Filip Krag, 1 Jul 2010, In: Danish Medical Bulletin (Online). 57, 7, p. B4163

    Research output: Contribution to journal › Review › Research › peer-review

  4. Published

    The impact of pancreatic enzyme supplementation on postprandial responses of glucagon-like Peptide-2 in patients with chronic pancreatitis and pancreatic exocrine insufficiency

    Knop, Filip Krag, Vilsbøll, Tina, Lund, A., Krarup, T., Holst, Jens Juul & Hornum, Mads, 6 Sep 2010, In: Journal of the Pancreas. 11, 5, p. 489-91 3 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  5. Published

    Glucagon suppression during OGTT worsens while suppression during IVGTT sustains alongside development of glucose intolerance in patients with chronic pancreatitis

    Knop, Filip Krag, Vilsbøll, Tina, Larsen, S., Madsbad, Sten, Holst, Jens Juul & Krarup, T. M., 24 Sep 2010, In: Regulatory Peptides. 164, 2-3, p. 144-50 7 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  6. Published

    Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes

    Solem, Espen Victor Jimenez, Rasmussen, M. H., Christensen, M. & Knop, Filip Krag, 1 Dec 2010, In: Current Opinion in Molecular Therapeutics. 12, 6, p. 790-7 8 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  7. Published

    Increased Postprandial Response of Glucagon-Like Peptide-2 in Patients with Chronic Pancreatitis and Pancreatic Exocrine Insufficiency

    Hornum, Mads, Pedersen, J. F., Larsen, S., Olsen, O., Holst, Jens Juul & Knop, Filip Krag, 2010, In: Pancreatology. 10, 2-3, p. 201-207 7 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  8. Published

    Incretin-based therapy and type 2 diabetes

    Hare, K. J. & Knop, Filip Krag, 1 Jan 2010, In: Vitamins and Hormones. 84, p. 389-413 25 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  9. Published

    Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes

    Hare, K. J., Vilsbøll, Tina, Holst, Jens Juul & Knop, Filip Krag, 1 Apr 2010, In: American Journal of Physiology: Endocrinology and Metabolism. 298, 4, p. E832-7 6 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  10. Published

    The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action

    Hare, K. J., Vilsbøll, Tina, Asmar, M., Deacon, Carolyn F., Knop, Filip Krag & Holst, Jens Juul, 1 Jul 2010, In: Diabetes. 59, 7, p. 1765-70 6 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

Previous 1 2 Next

ID: 40100368